Greenhall, GHB;
Salama, AD;
(2015)
What is new in the management of rapidly progressive glomerulonephritis?
Clinical Kidney Journal
, 8
(2)
143 - 150.
10.1093/ckj/sfv008.
Preview |
PDF
sfv008.pdf Download (264kB) |
Abstract
Rapidly progressive glomerulonephritis (RPGN) results from severe crescentic damage to glomeruli and leads to irreversible kidney failure if not diagnosed and managed in a timely fashion. Traditional treatment has relied on glucocorticoids and cyclophosphamide, with additional plasmapheresis for certain conditions. Here we describe updates in the management of RPGN, according to the underlying renal pathology. However, there remains a paucity of trials that have enrolled patients with more advanced renal disease, dialysis dependence or with RPGN, and we are therefore still reliant on extrapolation of data from studies of patients with a less severe form of disease. In addition, reporting bias results in publication of cases or cohorts showing benefit for newer agents in advanced disease or RPGN, but it remains unclear how many unsuccessful outcomes in these circumstances take place. Since clinical trials specifically in RPGN are unlikely, use of biologic registries or combination of sufficient sized cohort series may provide indications of benefit outside of a clinical trial setting and should be encouraged, in order to provide some evidence for the efficacy of therapeutic regimens in RPGN and advanced renal disease.
Type: | Article |
---|---|
Title: | What is new in the management of rapidly progressive glomerulonephritis? |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1093/ckj/sfv008 |
Publisher version: | http://dx.doi.org/10.1093/ckj/sfv008 |
Language: | English |
Additional information: | © The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
Keywords: | AKI, glomerulonephritis, IgA nephropathy, systemic lupus erythematosus, vasculitis |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine |
URI: | https://discovery.ucl.ac.uk/id/eprint/1468963 |
Archive Staff Only
View Item |